Tramadol HCl SR Pellets are pharmaceutical-grade multiparticulate pellets containing Tramadol Hydrochloride and designed for sustained-release oral dosage-form development. The pellet format provides a flexible platform for incorporating a controlled release profile into suitable capsule and multiparticulate formulations.
Tramadol Hydrochloride is identified by CAS Number 36282-47-0, with molecular formula C₁₆H₂₆ClNO₂ and molecular weight 299.84 g/mol. Tramadol Hydrochloride is also available commercially in sustained-release pellet formats. Multiple Indian pharmaceutical-pellet manufacturers list Tramadol Hydrochloride SR Pellets, with reported commercial loadings including 30%, 40%, 60% and 60% w/w depending on the manufacturer and product configuration. These commercial values should not be treated as the SDP specification unless confirmed by SDP.
Tramadol Hydrochloride SR Pellets are designed around a multiparticulate approach in which individual pellets can contain the active ingredient and, where applicable, a functional release-controlling coating or matrix system.
The sustained-release characteristics depend on the formulation composition, pellet structure, polymer system, coating level and manufacturing parameters. Therefore, Tramadol HCl SR Pellets Manufacturer in India specifications should be established according to the validated product formulation rather than applying API specifications directly to the finished pellets.
Commercial references demonstrate significant variation in Tramadol Hydrochloride pellet loading. For example, reported commercial products include 30% and 60%, while another manufacturer lists 40% and 60%. This variation confirms that active loading is product-specific.
Tramadol HCl SR Pellets can be used for:
Tramadol HCl SR Pellets may be manufactured using suitable pelletization, layering and functional-coating technologies. Depending on the formulation design, processing can be used to achieve the required pellet morphology, active loading, mechanical properties and release characteristics.
Important product parameters can include:
These parameters should be controlled according to the applicable finished-pellet specification.
Quality evaluation of Tramadol HCl SR Pellets may include:
The API identity and quality requirements should be evaluated against the applicable pharmacopoeial or approved product specification. Finished Tramadol HCl SR Pellets require their own validated acceptance criteria because the presence of excipients and release-controlling components changes the composition relative to the API.
The multiparticulate pellet format provides formulation developers with a flexible approach to sustained-release dosage-form development. Individual pellets can be engineered with appropriate formulation and coating characteristics, allowing the finished product to achieve its intended release profile.
Tramadol Hydrochloride pharmaceutical pellets can therefore be considered where a sustained-release pellet platform is required for capsule-based or other multiparticulate oral formulations.
Tramadol HCl SR Pellets can be packaged according to the applicable pharmaceutical product specification and bulk-handling requirements. Active loading, pellet size, release profile, packaging configuration and other technical parameters should be confirmed against the final approved specification.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 0.5% |
| Residue on Ignition | NMT 0.1% |
| Individual Impurity | NMT 0.5% |
| Water Content | NMT 1.0% |